• Petrels 15th International Congress with menopause, Prague, Czech Republic

Petrels 15th International Congress with menopause, Prague, Czech Republic

HEALTH OF WOMAN. 2016.10(116):19–23 
 

Petrels 15th International Congress with menopause, Prague, Czech Republic


Shurpac S. A.

Lviv national medical University named Danylo Galitsky


In Prague (Czech Republic) at 28 September – 1 October 2016 hosted the 15th International Congress on menopause. Оnce every 3 years there were about 1000 participants, experts in the field of menopause (gynecologists, endocrinologists, oncologists, pharmacologists, and others.) from all over the world.

On the congress were discussed aspects of transdermal estrogen use, cardiovascular disease in perimenopausal women, targeted approach for estrogen deficiency management, endocrine aspects of breast cancer, issues of breast screening, carcinogenic effects of different estrogens and progestins, and other important aspects of women’s health in «elegant age».

The greatest number of discussions was devoted to benefits and risks of menopausal hormone therapy. Speakers repeatedly noted that results of incorrectly conducted study Women’s Health Initiative (WHI) has led to an increasing of distrust and a sharp decline in use of menopausal hormone therapy, in many countries, which, ultimately reduce the possibility of timely and quality care for many women with, problems of menopausal transition.


Key words: 15th International Congress on menopause, transdermal estrogen, Women’s Health Initiative, menopausal hormone therapy.


REFERENCES

1. Henderson VW, Lobo RA. 2012. Climacteric. 15:229–34. https://doi.org/10.3109/13697137.2012.656254; PMid:22612608 PMCid:PMC3675220

2. Manson JE et al. 2013. JAMA. 310:1353–68. https://doi.org/10.1001/jama.2013.278040; PMid:24084921 PMCid:PMC3963523

3. Boardman et al. 2015. Cochrane Database Syst Rev. 3:CD002229.

4. Renoux C et al. 2010. BMJ. 340:2519.

5. Lobo RA, Clarkson TB. 2011. Menopause. 18:237–40. https://doi.org/10.1097/gme.0b013e318211745b

6. L’Hermite M. 2013. Climacteric. 16 Suppl 1:44. https://doi.org/10.3109/13697137.2013.808563; PMid:23848491

7. Updated 2013 International Meno-pause Society recommendations. Climacteric. 16:316–337. 2013. https://doi.org/10.3109/13697137.2013.795683; PMid:23672656

8. Siris ES et al. 2004. J Bone Miner Res. 19:1215-20. https://doi.org/10.1359/JBMR.040508; PMid:15231007

9. Barrett-Connor E et al. 2008. Osteoporos Int. 19:607-13. https://doi.org/10.1007/s00198-007-0508-8; PMid:18058055

10. Kanis JA et al. 2013. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). Osteoporos Int. 24:23-57. https://doi.org/10.1007/s00198-012-2074-y; PMid:23079689 PMCid:PMC3587294

11. Baber RJ, Panay N, Fenton A and the IMS Writing Group. 2016. IMS Recommendations on women’s midlife health and menopause hormone therapy 2016 Climacteric. 19:109–150.